《復牌公告》開拓藥業-B(09939.HK)澄清擬折讓13.6%配股 明日復牌
開拓藥業-B(09939.HK)公布,已向聯交所申請股份自明日(9月1日)起復牌。公司就先舊後新配股交易作出澄清,由於手民之誤,有關交易內容應為配售代理以每股13.94元,較公司昨日(30日)收市價每股16.14元折讓約13.6%,配售由公司主席童友之全資擁有的KT International Investment Limited (賣方)所持合共2,844.25萬股,相當於公司擴大後股本約7%。
其後賣方認購1,991萬股新股,即實際上減持853.25萬股公司股份,相當於公司已發行股本約2.2%,減持價格為每股13.94元,料所得款項淨額約為1.18億元,將用於償還賣方應付公司的貸款及利息。
公司預期,配售事項淨集資約2.73億元,擬用於普克魯胺的臨床開發及商業化以及福瑞他恩的臨床開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.